References

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination

10.1128/mbio.02901-25 · 2026 · External reference

Rethinking the evidence on COVID-19 in Africa

10.1016/s1473-3099(25)00071-4 · 2025 · External reference

Unresolved reference

External reference

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

10.1038/s41392-020-0191-1 · 2020 · External reference

Effectiveness of monovalent and bivalent COVID-19 vaccines

10.1016/s1473-3099(23)00379-1 · 2023 · External reference

Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2

10.1016/j.biopha.2022.113522 · 2022 · External reference

Unresolved reference

External reference

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027 (EMA/127531/2026)

2026 · External reference

Unresolved reference

External reference

Multivalent vaccines against new SARS-CoV-2 hybrid variants

10.1016/j.vacun.2022.06.002 · 2023 · External reference

Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1

10.1016/s1473-3099(25)00308-1 · 2025 · External reference

Virological characteristics of the SARS-CoV-2 XEC variant

10.1016/s1473-3099(24)00731-x · 2024 · External reference

Virological characteristics of the SARS-CoV-2 JN.1 variant

10.1016/s1473-3099(23)00813-7 · 2024 · External reference

Fast model selection for accurate phylogenetic estimates

10.1038/nmeth.4285 · 2017 · External reference

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

10.1038/s41591-021-01377-8 · 2021 · External reference

N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains

10.1016/j.csbj.2021.10.004 · 2021 · External reference

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave

10.1186/s44263-025-00201-6 · 2025 · External reference

Longitudinal epidemiology and variant dynamics of SARS-CoV-2 in Coastal Kenya (2020–2025): clinical features and wave patterns

10.1093/ofid/ofag084 · 2026 · External reference

Low transmission of the globally dominant recombinant SARS-coV-2 XFG variant in Kenya, may-july 2025

10.1101/2025.11.10.25338449 · 2025 · External reference

Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward

10.1080/21645515.2022.2034457 · 2022 · External reference

Immune evasion, cell-cell fusion, and spike stability of the SARS-coV-2 XEC variant: role of glycosylation mutations at the N-terminal domain

10.1101/2024.11.12.623078 · 2024 · External reference

Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants

10.1016/j.celrep.2024.114520 · 2024 · External reference

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

10.1038/s41586-022-04465-y · 2022 · External reference

Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1

10.1016/s1473-3099(25)00015-5 · 2025 · External reference

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya

10.1186/s12879-024-10367-3 · 2024 · External reference

Persistent SARS-CoV-2 infection: significance and implications

10.1016/s1473-3099(23)00815-0 · 2024 · External reference

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

10.1016/j.celrep.2025.116440 · 2025 · External reference

IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era

10.1093/molbev/msaa015 · 2020 · External reference

Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya

10.1093/ve/veaf035 · 2025 · External reference

Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro

10.1016/j.ijid.2022.11.041 · 2023 · External reference

Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya

10.12688/wellcomeopenres.17661.1 · 2022 · External reference

Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events

10.1038/s41392-022-00992-2 · 2022 · External reference

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

10.1038/s41467-024-46490-7 · 2024 · External reference

10.17504/protocols.io.bp2l6n26rgqe/v4

10.17504/protocols.io.bp2l6n26rgqe/v4 · 2024 · External reference

The statistical analysis of immunohaematological data

10.2450/2008.0001-08 · 2008 · External reference

Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants

10.1126/science.abm0811 · 2022 · External reference

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

10.1038/s41591-022-02092-8 · 2023 · External reference

Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies

10.3389/fimmu.2021.830527 · 2022 · External reference

Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses

10.1016/s1473-3099(23)00588-1 · 2023 · External reference

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host

10.1038/s41392-023-01449-w · 2023 · External reference

Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe acute respiratory illness cases in selected health facilities in Ethiopia

10.3389/fpubh.2025.1714899 · 2026 · External reference

Immune imprinting of SARS-CoV-2 responses: changing first immune impressions

10.1128/msphere.00758-23 · 2024 · External reference

Unresolved reference

External reference

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

10.1038/s41586-022-05053-w · 2022 · External reference

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

10.1016/j.cell.2022.12.018 · 2023 · External reference

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

10.1080/22221751.2024.2402880 · 2024 · External reference

Unresolved reference

External reference

Mapping SARS-CoV-2 antigenic relationships and serological responses

10.1126/science.adj0070 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines

10.1016/s2666-5247(22)00335-4 · 2023 · External reference